Log in
E-mail
Password
Show password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Settings
Settings
Dynamic quotes 
OFFON

INTUITIVE SURGICAL, INC.

(ISRG)
  Report
SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
SummaryMost relevantAll NewsAnalyst Reco.Other languagesPress ReleasesOfficial PublicationsSector newsMarketScreener Strategies

Intuitive Surgical : Wells Fargo Adjusts Intuitive Surgical's Price Target to $381 from $354, Keeps Overweight Rating

10/20/2021 | 12:06pm EST


ę MT Newswires 2021
All news about INTUITIVE SURGICAL, INC.
01/18CORRECTION : Goldman Sachs Adjusts Price Target for Agiliti to $32 From $37, Maintains Buy..
MT
01/18Goldman Sachs Adjusts Price Target for Intuitive Surgical to $32 From $37, Maintains Bu..
MT
01/12Intuitive Surgical Sees 17% Rise in Q4 Revenue
MT
01/12Intuitive Surgical Sees 4Q Revenue Topping Street Views
DJ
01/12INTUITIVE SURGICAL : ANNOUNCES PRELIMINARY FOURTH QUARTER AND FULL YEAR 2021 RESULTS - For..
PU
01/12INTUITIVE SURGICAL INC : Results of Operations and Financial Condition (form 8-K)
AQ
01/12Intuitive Announces Preliminary Fourth Quarter and Full Year 2021 Results
AQ
01/11NORTH AMERICAN MORNING BRIEFING : Inflation, Rate -3-
DJ
01/10BTIG Upgrades Intuitive Surgical to Buy from Neutral, Sets $372 Price Target
MT
2021Intuitive Surgical Says US FDA Approves SureForm 30 Stapler for Surgical Use
MT
More news
Analyst Recommendations on INTUITIVE SURGICAL, INC.
More recommendations
Financials (USD)
Sales 2021 5 721 M - -
Net income 2021 1 668 M - -
Net cash 2021 2 405 M - -
P/E ratio 2021 66,2x
Yield 2021 -
Capitalization 106 B 106 B -
EV / Sales 2021 18,0x
EV / Sales 2022 15,7x
Nbr of Employees 8 081
Free-Float -
Chart INTUITIVE SURGICAL, INC.
Duration : Period :
Intuitive Surgical, Inc. Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends INTUITIVE SURGICAL, INC.
Short TermMid-TermLong Term
TrendsBearishBearishBullish
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus OUTPERFORM
Number of Analysts 18
Last Close Price 295,49 $
Average target price 354,93 $
Spread / Average Target 20,1%
EPS Revisions
Managers and Directors
Gary S. Guthart Chief Executive Officer & Director
Calvin Darling Senior Director-Finance & Investor Relations
Jamie E. Samath Chief Financial Officer
Craig H. Barratt Chairman
Myriam J. Curet Chief Medical Officer & Executive Vice President
Sector and Competitors